18317064

Source:http://linkedlifedata.com/resource/pubmed/id/18317064

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005940, umls-concept:C0029431, umls-concept:C0030705, umls-concept:C0036525, umls-concept:C0038952, umls-concept:C0205250, umls-concept:C0257685, umls-concept:C0441655, umls-concept:C0684249, umls-concept:C1522484, umls-concept:C2745888
pubmed:issue	3
pubmed:dateCreated	2008-3-4
pubmed:abstractText	Bone metastases from non-small cell lung cancer (NSCLC) are associated with skeletal-related events (SREs) and elevated levels of N-telopeptide of type I collagen (NTX) in some patients. Zoledronic acid (ZOL) reduces SRE risk and NTX levels.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/18317064-18670319
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101274235
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Alkaline Phosphatase, http://linkedlifedata.com/resource/pubmed/chemical/Bone Density Conservation Agents, http://linkedlifedata.com/resource/pubmed/chemical/Collagen Type I, http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates, http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles, http://linkedlifedata.com/resource/pubmed/chemical/Peptides, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological, http://linkedlifedata.com/resource/pubmed/chemical/collagen type I trimeric..., http://linkedlifedata.com/resource/pubmed/chemical/zoledronic acid
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1556-1380
pubmed:author	pubmed-author:BrownJanet EJE, pubmed-author:ColemanRobert ERE, pubmed-author:CookRichard JRJ, pubmed-author:HirshVeraV, pubmed-author:LangerCorey JCJ, pubmed-author:LiptonAllanA, pubmed-author:MajorPierre PPP, pubmed-author:SmithMatthew RMR
pubmed:issnType	Electronic
pubmed:volume	3
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	228-36
pubmed:dateRevised	2008-11-25
pubmed:meshHeading	pubmed-meshheading:18317064-Adult, pubmed-meshheading:18317064-Aged, pubmed-meshheading:18317064-Aged, 80 and over, pubmed-meshheading:18317064-Alkaline Phosphatase, pubmed-meshheading:18317064-Bone Density Conservation Agents, pubmed-meshheading:18317064-Bone Neoplasms, pubmed-meshheading:18317064-Canada, pubmed-meshheading:18317064-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:18317064-Collagen Type I, pubmed-meshheading:18317064-Diphosphonates, pubmed-meshheading:18317064-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:18317064-Female, pubmed-meshheading:18317064-Follow-Up Studies, pubmed-meshheading:18317064-Humans, pubmed-meshheading:18317064-Imidazoles, pubmed-meshheading:18317064-Lung Neoplasms, pubmed-meshheading:18317064-Male, pubmed-meshheading:18317064-Middle Aged, pubmed-meshheading:18317064-Osteoclasts, pubmed-meshheading:18317064-Peptides, pubmed-meshheading:18317064-Retrospective Studies, pubmed-meshheading:18317064-Time Factors, pubmed-meshheading:18317064-Treatment Outcome, pubmed-meshheading:18317064-Tumor Markers, Biological, pubmed-meshheading:18317064-United States
pubmed:year	2008
pubmed:articleTitle	Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
pubmed:affiliation	McGill University Health Centre, Montreal, Quebec, Canada. vera.hirsh@muhc.mcgill.ca
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III